Slate Medicines
PrivateLast Round
Series A
Feb 24, 2026
Total Funding Raised
$130M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Slate Medicines operates in Healthcare & Life Sciences and is based in Raleigh, North Carolina. Its latest recorded funding round was a Series A round in February 2026.
Slate Medicines is a biotechnology company developing next-generation therapeutics targeting PACAP for the treatment and prevention of migraine and other headache disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Slate Medicines Comparables
Compare Slate Medicines with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Vedana Therapeutics | 90% | |
| DartsBio Pharmaceutical (Guangdong) Co., Ltd. | 85% | |
| InMed Pharmaceuticals | 84% |
For institutional investors. Book with your work email.
Slate Medicines Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Slate Medicines Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion Capital Partners | Series A |
| RA Capital Management | Series A |
| Forbion | Series A |
| Foresite Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 26, 2026
Grew 100% QoQ from 7 to 14 employees.
- Sep 3, 2026
Grew 43% QoQ, from 7 to 10 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresOct 20, 2026
Slate Medicines appoints Stephen K. Brannan, MD, to its Board of Directors alongside John D. Young in North Carolina on Oct 20th '26.
- hiresSep 14, 2026
Slate Medicines appoints Kenneth Koblan, PhD, as Chief Scientific Officer in North Carolina on Sep 14th '26, as it expands its leadership team.
- is_developingAug 18, 2026
Slate Medicines is developing SLTE-2100 as another migraine treatment; the program is in lead optimization and is expected to enter clinical trials in H2 '27.
- receives_financingAug 17, 2026
Slate Medicines secures commitments for a $245M oversubscribed concurrent private placement from healthcare investors led by Frazier Life Sciences and including Forbion, RA Capital Management, Deep Track Capital, Foresite Capital, OrbiMed, RTW Investments, and Mingxin Capital, in connection with its merger.
For institutional investors. Book with your work email.
Slate Medicines Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Slate Medicines's valuation, stock price, and market status.
Is Slate Medicines a public or private company?
Slate Medicines is a private company.
What is the current stock price of Slate Medicines?
Slate Medicines is a private company, so its shares have no public market price. Caplight tracks Slate Medicines's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Slate Medicines worth (valuation)?
Valuation information for Slate Medicines is not publicly available.
Can I buy Slate Medicines stock?
Slate Medicines shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Slate Medicines's last funding round?
Slate Medicines's most recent funding round was Series A on February 24, 2026.
Who are the main investors in Slate Medicines?
Key investors in Slate Medicines include Forbion Capital Partners, RA Capital Management, Forbion, Foresite Capital.
Will Slate Medicines IPO soon?
No public IPO plans have been announced for Slate Medicines.
How can I track Slate Medicines secondary market activity?
Caplight tracks bids, offers, and trades in Slate Medicines's shares on secondary markets.